Advertisements

Lucrin depot

Quick links to important sections

Lucrin depot

Selected form

Advertisements
Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Lucrin depot

Quick Facts

Property Description
Active ingredient Leuprorelin acetate
Form Powder for suspension for injection (Depot)
Pharmacological class GnRH agonist (Gonadotropin-releasing hormone agonist)
General purpose To suppress sex hormone production
Origin Synthetic nonapeptide analogue

What Type of Medicine is Lucrin Depot?

Lucrin depot is a prescription-only medicine used in endocrine therapy, belonging to the pharmacological class of Gonadotropin-releasing hormone (GnRH) agonists. Its active compound is Leuprorelin acetate, which is a synthetic nonapeptide analogue of the naturally occurring Luteinizing Hormone-Releasing Hormone (LHRH). This composition allows the medication to modulate the body's central hormonal control system. As a GnRH analogue, leuprorelin functions by achieving medically induced sex hormone suppression. This agent is used clinically to achieve deep and sustained hormonal downregulation.


Understanding the Depot Formulation and Composition

Lucrin depot is supplied as a powder for suspension for injection, designed as a sustained-release formulation intended for subcutaneous or intramuscular administration. The key to its long-acting function is the "depot" mechanism, where the Leuprorelin acetate is encapsulated within tiny, biodegradable lyophilized microspheres. This design ensures the single active ingredient is released slowly and consistently over an extended period following injection. This delivery system provides continuous, stable drug levels, which differentiates the depot form from daily injectable leuprorelin formulations.


What is the General Purpose of Leuprorelin?

The general purpose of Leuprorelin is to achieve and maintain a significant and sustained reduction in the body's production of sex hormones, such as testosterone and estrogen. It accomplishes this by initially stimulating and then quickly desensitizing the Hypothalamic-Pituitary-Gonadal (HPG) axis, the body’s regulatory system for these hormones. This sustained action leads to an intentional low-hormone state. This state is utilized to manage the progression of various hormone-sensitive conditions, such as when controlling the hormonal environment in certain adult patients or in managing precocious puberty in pediatric patients, by reducing the circulating hormones that these conditions rely on.

Regulatory References

  1. NIH LiverTox: Leuprolide
Advertisements

What side effects are possible with Lucrin depot?

Possible Side Effects and Safety Information

The safety profile of Lucrin depot is characterized by effects that arise primarily from the intended, sustained suppression of sex hormones, alongside specific systemic and administration-site reactions. Official regulatory documents classify potential adverse reactions by frequency and the body system affected.

Frequency-Classified Adverse Reactions

The most commonly reported effects, classified as Very Common or Common in regulatory labels, include generalized symptoms such as hot flashes, sweating, fatigue, and headache. Reactions at the injection site, joint pain (arthralgia), and disturbances in the gastrointestinal system are also frequently documented. Less common or rare reactions reported in postmarketing surveillance include severe depression (including suicidal ideation), convulsions, and serious skin reactions.


Serious Adverse Reactions and Safety Patterns

Regulatory documents highlight several serious adverse reactions. A transient Tumor Flare—a temporary worsening of underlying symptoms—may occur during the first few weeks of therapy due to the initial hormonal surge. Long-term use is associated with an increased risk of developing metabolic issues (such as hyperglycemia and diabetes) and cardiovascular events (including myocardial infarction and stroke), as documented in regulatory warnings for the drug class. Loss of Bone Mineral Density is also a documented risk with chronic use.


Population-Specific Considerations

Lucrin depot is contraindicated during pregnancy due to the potential for fetal harm. In pediatric patients receiving treatment for central precocious puberty, an initial rise in sex hormones may lead to a temporary increase in signs of puberty. Furthermore, specific safety notes advise caution and monitoring for individuals with a history of cardiac risk factors, epilepsy, or severe depression, as outlined in the official prescribing information.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Lucrin Depot (leuprorelin acetate) is primarily characterized by the absence of specific human data concerning overdosage. Prescribing information explicitly states there is no documented experience of overdosage in human clinical trials for the depot formulation.

Due to this constraint, the official management approach for a suspected overexposure is to be symptomatic and supportive, and no specific antidote is known or listed in the product information. Patients should be monitored closely following any suspected overdosage. Additionally, official regulatory notes indicate that administration at higher than the recommended dosages has been associated with localized reactions, such as the formation of sterile abscesses at the injection site.


Action Mandated by Regulators

Immediate medical attention is required for the onset of any severe, unexpected, or potentially life-threatening symptoms. This regulatory directive includes seeking prompt help for signs indicative of acute conditions detailed in the warnings, such as pituitary apoplexy (sudden severe headache or visual changes) or severe cutaneous adverse reactions like Stevens-Johnson syndrome (SJS). The official guidance emphasizes that all treatment must align with the presentation of acute symptoms, underscoring the necessity of urgent professional care in these acute scenarios.

Advertisements

Therapeutic Uses of Lucrin depot

Lucrin Depot: Main Uses and Benefits in Symptom Management

Lucrin Depot is applied across domains where additional symptomatic support is needed, primarily in situations involving certain distressing symptoms. The medicine is commonly used to help manage symptoms related to systemic imbalance that interfere with daily functioning, providing supportive relief during periods of heightened discomfort. This application is relevant in clinical settings marked by heightened patient distress.


Easing Discomfort in Symptomatic Conditions

This therapeutic domain is relevant for easing symptom clusters that may become intense or disruptive in conditions characterized by periods of heightened symptoms or episodic or fluctuating manifestations. It contributes to improved day-to-day comfort, assisting with maintaining functional stability when symptoms escalate temporarily.


Supporting Stabilization During Acute Symptom Periods

Lucrin Depot is also applied in clinical settings that involve acute or unstable symptom patterns, particularly in situations involving conditions associated with acute or disruptive episodes. This application offers symptomatic relief, helping to maintain a sense of stability when symptoms are more noticeable and potentially overwhelming.


Quick Facts

Quick Fact: Relief is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability in conditions marked by increased physiological stress.

Regulatory References

  1. New Zealand Medsafe Data Sheet
Advertisements

Eligibility and Restrictions for Use

Official Regulatory Eligibility Profile

Eligibility for Lucrin Depot (Leuprorelin acetate) is strictly defined by regulatory documents, which establish clear rules on who is permitted, restricted, or prohibited from using the medicine based on patient population and pre-existing conditions.

Eligibility Classification Populations/Conditions
Absolutely Contraindicated Patients with a known hypersensitivity to GnRH, GnRH agonists, or any component of the formulation. Women who are pregnant, may become pregnant, or are breastfeeding. Women with undiagnosed abnormal uterine bleeding.
Approved Populations Adult Men (for advanced prostatic cancer). Adult Pre-menopausal Women (for endometriosis or uterine fibroids). Pediatric Patients (for Central Precocious Puberty, CPP).

Age-Related Eligibility

Use is not recommended in children under two years of age for the CPP indication. For female indications, the medicine is not indicated for use in geriatric women (over 65). In contrast, use is established in geriatric men for the treatment of prostate cancer.

Conditional Use and Restrictions

Therapy is limited in duration for women with major risk factors for decreased Bone Mineral Density (BMD), often requiring the addition of other medicines to reduce bone loss risk. Men with prostatic cancer at risk of spinal cord compression or ureteral obstruction must be closely monitored and supervised due to the risk of temporary symptom worsening.

Advertisements

What should I know about interactions with other medicines?

Lucrin depot, containing leuprolide acetate, is a peptide that is primarily degraded by peptidases and not by cytochrome P-450 enzymes. Therefore, pharmacokinetic drug interactions mediated by the P-450 enzyme system are not expected to occur.

However, several pharmacodynamic interactions and clinical requirements must be considered:

  • Hormonal Contraception: Only non-hormonal methods of contraception should be used during treatment, as hormonal contraceptives are not indicated.
  • Bone Mineral Density (BMD) Loss: The risk of BMD loss may be increased when Lucrin depot is used concomitantly with other medicines that can decrease bone mineral density, such as corticosteroids or certain anticonvulsants.
  • Convulsions: Use with caution when Lucrin depot is co-administered with medicines that have been associated with convulsions, including certain SSRIs (Selective Serotonin Reuptake Inhibitors) or Bupropion. This combination may increase the risk, particularly in patients with a history of seizures or predisposing factors.
  • Combination Therapy: For certain indications, the product is explicitly listed for concomitant use with other specific agents. For example, norethindrone acetate (add-back therapy) is used to mitigate BMD loss and is mandatory for retreatment in endometriosis. Iron therapy is indicated for concomitant use in the preoperative management of uterine fibroids with anemia.
Advertisements

Mechanism of Action

The mechanism of action for Lucrin depot (leuprolide) is centered on modulating the hypothalamic-pituitary-gonadal (HPG) axis. As a synthetic GnRH agonist, leuprolide initially binds to the gonadotropin-releasing hormone (GnRH) receptors on pituitary gland cells. This binding causes a transient stimulation and subsequent release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), leading to a temporary surge in downstream sex hormones. This initial event is known as the flare effect.

The primary mechanistic action follows this initial phase. The drug's continuous, non-pulsatile presence, facilitated by the depot formulation, causes the pituitary GnRH receptors to become desensitized and downregulated.

This sustained interference with the central signaling cascade functionally suppresses the pituitary's ability to release LH and FSH. The resultant removal of these key signaling hormones leads to the suppression of gonadal steroidogenesis, resulting in a sustained reduction in systemic testosterone and estrogen levels.

Advertisements

Dosage and Administration Information

Lucrin Depot Administration Instructions

Lucrin depot (leuprolide acetate) is a depot suspension that must be administered as a single intramuscular (IM) injection by a healthcare professional. The frequency of administration depends on the specific dosage strength being used:

  • Monthly Administration: 3.75 mg, 7.5 mg, 11.25 mg, or 15 mg doses are given once every month (every 4 weeks).
  • 3-Month Administration: 11.25 mg or 22.5 mg doses are given once every three months (every 12 weeks).
  • Long-Acting Administration: 30 mg or 45 mg doses are given every four or six months, respectively.

Preparation and Procedure

Before injection, the lyophilized microsphere powder must be reconstituted using the provided diluent within the dual-chamber syringe. The healthcare provider must visually inspect the powder for clumping or caking; if present, the product must not be used. The diluent is slowly pushed into the front chamber, and the syringe is then gently shaken to create a uniform, milky suspension.

The suspension must be administered immediately after reconstitution or discarded if not used within two hours, as it contains no preservative. The injection is given at a 90-degree angle into the gluteal area, anterior thigh, or deltoid, and the injection sites should be alternated periodically. The full contents of the syringe must be injected, and fractional doses or combinations of doses are prohibited due to differing release characteristics.

Pediatric Dosing

For pediatric patients, the initial dose (e.g., 7.5 mg, 11.25 mg, or 15 mg for 1-month administration) is individualized based on the child's body weight and may be adjusted to ensure adequate hormonal suppression.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lucrin Depot

This overview summarizes the type of research conducted for Lucrin depot, focusing on the populations studied, the outcomes measured, and the overall scientific evidence context. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Evidence for Use in Advanced Prostate Cancer

Research related to this indication included Randomized Controlled Trials (RCTs) and open-label Phase 3 studies focused on adult males with hormone-sensitive disease. Researchers monitored the achievement and maintenance of testosterone suppression and changes in Prostate-Specific Antigen (PSA) levels. Studies reported patterns observed in achieving these targets. Research is limited regarding long-term, direct comparisons of different depot formulations using clinical outcomes such as overall survival (OS), with many foundational studies focusing mainly on biochemical marker attainment.

Evidence for Use in Central Precocious Puberty (CPP)

The evidence base for children with CPP involves Phase 3 multicenter, open-label, single-arm studies. Research examined the achievement of target levels of central and peripheral sex hormones to pre-pubertal levels. Researchers monitored physical signs of puberty and the rate of bone age advancement in children aged 2–11 years. Certainty remains low for some aspects, as the majority of the evidence is derived from non-comparative trials focused on achieving hormone suppression.

Evidence for Use in Endocrine-Responsive Breast Cancer

Research utilized RCTs examining the medicine as a component of combination therapy in premenopausal women. Researchers primarily examined long-term clinical outcomes such as Disease-Free Survival (DFS) and Overall Survival (OS), alongside monitoring the achievement of Ovarian Function Suppression (OFS). Research is limited to combination therapy, and comparative evidence for its use as a single agent in this context is lacking.

Long-Term Studies and What is Still Uncertain

Research has explored outcomes over extended observation periods for all indications, including follow-up studies extending several years. However, long-term effects are not well characterized for all specific outcomes, and data are still emerging regarding certain long-term clinical endpoints. Evidence quality varies across studies, with a significant amount of data derived from non-comparative trials, which differ structurally from blinded, randomized trials. There is limited information for long-term outcomes focused on complex clinical endpoints beyond the primary biochemical markers initially monitored.

Key Studies & References

  1. Low Nadir Testosterone With Leuprolide Acetate for Prostate Cancer (Pivotal trials for subcutaneous leuprolide acetate, pooled analysis)
  2. Long-Term Efficacy and Safety of Leuprorelin Treatment in Children with Central Precocious Puberty: A Systematic Review and Meta-Analysis
  3. Hormone therapy | Prostate Cancer UK (Context for hormone suppression goal/markers)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Lucrin depot (FAQ)

Q: Is Lucrin depot the same as Lupron?

A: Lucrin depot and Lupron share the same active ingredient, leuprolide acetate. Lupron is the brand name used in certain regions, while Lucrin depot is used in others. Official sources confirm that both products are formulations of the same primary drug compound.

Q: How quickly does Lucrin depot start working?

A: The mechanism of Lucrin depot involves an initial hormonal surge before the main suppressive effect starts. Official product information indicates that therapeutic hormone suppression, such as achieving low testosterone or estrogen levels, is described in regulatory studies as typically occurring within the first four weeks following the injection.

Q: How long does the effect of one Lucrin depot injection last?

A: The drug's name 'depot' refers to its sustained-release design, which is intended to provide a continuous effect over an extended period. Depending on the dose prescribed, one injection is formulated to last for continuous release over one month, three months, four months, or six months to maintain consistent hormonal suppression.

Q: Is it normal to feel worse before feeling better when starting Lucrin depot?

A: Regulatory documents note that the initial hormonal surge can lead to a transient worsening of symptoms during the first few weeks of therapy. This temporary effect is part of the drug's mechanism before sustained hormone suppression begins.

Q: What kind of monitoring or tests are usually done while taking Lucrin depot?

A: Monitoring typically involves laboratory tests to measure sex hormone levels (like testosterone or estrogen) to ensure effective suppression. Due to associated risks, monitoring for changes in blood sugar (glucose/HbA1c) and serum lipids (cholesterol/triglycerides) is also described as necessary, according to official product information.

Q: Can Lucrin depot affect my mood or emotions?

A: Official labeling reports that side effects affecting mood and emotions, such as depression and emotional lability (mood changes), have been observed. In children, emotional symptoms including irritability and crying have also been reported in clinical experience.

Q: Does Lucrin depot cause weight gain?

A: Official adverse reaction lists indicate that weight gain is a commonly reported side effect for Lucrin depot in some populations. However, weight loss has also been reported in other patient groups, meaning effects can vary.

Q: Is hair loss a possible side effect of Lucrin depot?

A: Changes in hormone levels can sometimes affect hair growth. Regulatory documents often list adverse reactions such as hair thinning or alopecia (hair loss) as potential events related to the hormone suppression caused by the medication.

Q: Do hot flashes from Lucrin depot eventually go away?

A: Hot flashes are a very common and expected side effect because the drug creates a low-hormone state. While the duration is often tied to the length of treatment, official information describes the use of add-back therapy as a measure sometimes used to reduce hot flashes and related symptoms.

Q: Can people with a history of heart problems use Lucrin depot?

A: Official warnings and safety information describe that men with pre-existing cardiovascular risk factors are populations requiring close clinical monitoring. The drug can also potentially affect the heart's electrical activity (QT interval), which requires careful consideration.

Q: Can Lucrin depot affect bone density?

A: Yes, regulatory information documents that decreased bone mineral density (BMD) is a known risk, particularly with the long-term use of GnRH agonists like leuprolide acetate. For certain female indications, the duration of therapy is limited to help manage this documented concern.

Q: What happens if a Lucrin depot injection is delayed?

A: Consistent dosing is essential for maintaining therapeutic hormone suppression. Official safety information warns that if a dose is missed or delayed, the necessary hormonal suppression may not be maintained, which could lead to a return of symptoms associated with the underlying condition.

Q: Can Lucrin depot affect fertility in women after treatment is stopped?

A: Official clinical studies report that the hormonal suppression caused by Lucrin depot is generally reversible. The resumption of normal menstrual function and ovulation is typically reported once the treatment has been fully stopped.

Q: Can men using Lucrin depot still father children?

A: The drug's purpose is to create a state of sustained hormonal suppression, which is expected to significantly impair the capacity to father children. The suppressive effect is described as generally reversible once treatment is stopped.

Q: What should I know about driving or operating machinery while on Lucrin depot?

A: Side effects of the drug, such as dizziness, fatigue, and vision disturbances, are noted in regulatory labels. Official guidance notes that due to these potential effects, caution may be necessary when performing tasks that require full attention, such as driving or operating machinery.

Q: How is the dose of Lucrin depot determined?

A: The prescribed dose is determined based on the specific condition being managed, such as prostate cancer, uterine fibroids, or Central Precocious Puberty (CPP). For pediatric patients, the dose is individualized based on the child's body weight and the required degree of hormonal suppression, according to regulatory guidelines.

Q: What is Lucrin depot used for in women specifically?

A: According to official indications, Lucrin depot is used in adult pre-menopausal women for the management of symptoms associated with endometriosis. It is also indicated for the pre-operative management of uterine fibroids to help improve anemia (low iron levels in the blood).

Q: What is Lucrin depot used for in men specifically?

A: Official indications state that Lucrin depot is used in men for the palliative treatment of advanced prostatic cancer. Its role is to achieve sustained suppression of testosterone, which is a key growth factor for prostate cancer cells.

Q: Does Lucrin depot always cause menopausal symptoms in women?

A: The drug's purpose is to induce a low-estrogen state, which often results in symptoms consistent with menopause. While symptoms like hot flashes are classified as Very Common and are highly frequent, the occurrence of any side effect can vary among individuals.

Q: Does Lucrin depot have a risk of affecting blood sugar levels?

A: Official warnings note that the use of this drug class, particularly in men, may lead to metabolic changes, including an increased risk of hyperglycemia (high blood sugar). This may be a risk factor for or sign of diabetes mellitus, and clinical monitoring of blood sugar is described as necessary.

Q: Are there any age limits for who can use Lucrin depot?

A: Yes, age limits vary based on the indication. For pediatric use in Central Precocious Puberty, there are specific age guidelines. For adult female indications, the medicine is not indicated for geriatric women (over 65), while use is established in geriatric men for prostate cancer.

Q: Why is Lucrin depot sometimes used before surgery?

A: For women with uterine fibroids, Lucrin depot is sometimes used before surgery to help reduce heavy vaginal bleeding. This use is intended to improve the patient's anemia (low red blood cell count) prior to the surgical procedure.

Q: Is it normal to have a small lump or hardening after a Lucrin depot injection?

A: While common side effect lists include redness and swelling at the site, regulatory documents also report other localized reactions, including the formation of an abscess or a sunken area of skin near the injection site. These reactions indicate that local tissue changes can occur.

Q: How long after stopping Lucrin depot do hormone levels typically return to normal?

A: The suppression of sex hormones is a reversible effect. Official documents state that the time for hormone levels to return to pre-treatment levels can vary depending on the patient and the specific formulation used, but this reversal generally occurs within a few weeks to months after the last injection is received.

Q: Can Lucrin depot affect cholesterol levels?

A: Yes, regulatory warnings state that the use of this class of medicine, particularly in men, may lead to metabolic changes. These changes can include hyperlipidemia, which involves high levels of lipids like cholesterol and triglycerides. Monitoring of serum lipids is typically advised.

Q: What are the known risks of long-term use of Lucrin depot?

A: Official warnings document that prolonged use is associated with several risks. These include a documented risk of decreased bone mineral density, metabolic changes (like diabetes and high cholesterol), and certain cardiovascular events in men (such as heart attack or stroke).

Q: Are there any known issues with alcohol consumption while using Lucrin depot?

A: Regulatory sources advise that both the drug and alcohol can cause similar side effects, such as nausea, upset stomach, or dizziness. To prevent the worsening of these potential effects, limiting or avoiding alcohol consumption may be a component of clinical management.

Q: Is Lucrin depot used to treat pain?

A: Lucrin depot is approved for the management of underlying conditions like endometriosis and uterine fibroids. Although its primary action is hormone suppression, a clinical benefit in treating these conditions is the resulting relief of associated pain.

Q: What are the components of the Lucrin depot injection kit?

A: The injection kit typically contains a lyophilized powder (the leuprolide acetate microspheres) in one chamber of a syringe and a diluent (sterile liquid) in the other chamber. The kit often also includes the necessary needle and plunger rod for preparation and administration by a healthcare professional.

Q: Can Lucrin depot affect sleep quality?

A: Official adverse reaction lists indicate that insomnia (difficulty falling or staying asleep) has been reported as a side effect. This suggests that the medication may have an effect on a patient's sleep quality.

Q: Can Lucrin depot cause headaches or migraines?

A: Official safety documents list headache as a very commonly reported side effect. Furthermore, some regulatory labels for leuprolide formulations specifically include migraine in the list of adverse reactions.

Advertisements

How should Lucrin depot be stored and disposed of?

The storage and disposal of Lucrin Depot (leuprolide acetate) must strictly follow official regulatory guidelines to maintain product integrity and safety.

Storage Requirements

The dual-chamber syringe kit must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be stored in its original container and protected from light. It is explicitly stated in labeling that the product must not be frozen.

Stability and Handling

Once the suspension is prepared, it has a limited stability period. The regulatory instructions mandate that the suspension must be injected immediately after mixing. If the product is not administered immediately, it must be discarded if not used within two hours.

Disposal and Safety

To prevent accidental exposure, the medicine must be kept out of the sight and reach of children. Unused medicine, expired doses, and all materials from the injection kit must be disposed of according to local regulations for pharmaceutical waste and should not be placed in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lucrin depot found in:

A-Z Index: